Evenity Archives -

NICE has reversed its stance on UCB and Amgen’s severe osteoporosis therapy Evenity, saying out can be prescribed

NICE ends UK access disparity to osteoporosis drug Evenity

https://pharmaphorum.com/news/nice-ends-uk-access-disparity-to-osteoporosis-drug-evenity/

Amgen’s second quarter revenues were down 3% as competition pegged back its off-patent drugs Sensipar and Neulasta, but

Cancer update buoys Amgen despite Q2 sales fall

https://pharmaphorum.com/news/cancer-update-buoys-amgen-despite-q2-sales-fall/

Amgen and UCB have suffered another setback as they try to build momentum for Evenity, their new antibody

CHMP says no to Amgen’s osteoporosis drug Evenity

https://pharmaphorum.com/news/chmp-says-no-to-amgens-osteoporosis-drug-evenity/

Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down

At long last, Amgen/UCB score FDA okay for Evenity

https://pharmaphorum.com/news/at-long-last-amgen-ucb-score-fda-okay-for-evenity/

Amgen and UCB have resubmitted their application for US approval of Evenity as an osteoporosis treatment, hoping that

Amgen and UCB re-file Evenity for US approval

https://pharmaphorum.com/news/amgen-ucb-evenity-fda-filing/

Evenity